博思軟件(300525.SZ):副總經理鄭升尉完成減持 累計減持35萬股
格隆匯1月8日丨博思軟件(300525.SZ)公佈,公司副總經理、財務總監鄭升尉計劃自減持計劃披露之日起十五個交易日後的六個月內,以大宗交易或集中競價方式減持公司股份不超過35萬股(即不超過公司當時總股本的0.1646%)。
截至2020年1月7日,鄭升尉通過集中競價交易方式累計減持公司股份33.09萬股,佔公司總股本的0.1546%,減持公司股份數量較其預披露減持計劃數量已過半。截至2020年1月8日,鄭升尉通過集中競價交易方式累計減持公司股份35萬股,佔公司總股本的0.1636%,本次減持計劃已實施完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.